Schernberg Antoine, Moureau-Zabotto Laurence, Rivin Del Campo Eleonor, Escande Alexandre, Ducreux Michel, Nguyen France, Goere Diane, Chargari Cyrus, Deutsch Eric
Radiotherapy Department, Gustave Roussy Cancer Campus, Villejuif, France.
Radiation Oncology Department, Institut Paoli-Calmettes, Marseille, France.
Oncotarget. 2017 Feb 14;8(7):11579-11588. doi: 10.18632/oncotarget.14584.
To investigate the prognostic value of leukocyte and neutrophil count as biomarkers in patients with locally advanced esophageal squamous cell carcinoma (SCC) undergoing exclusive chemoradiation.
A total of 126 patients were identified. Respectively, 33% and 35% displayed baseline leukocytosis and neutrophilia. Estimated 3-year OS and PFS from chemoradiation completion were 31% and 25%, respectively. In univariate analysis, both leukocytosis and neutrophilia were associated with worse OS, PFS, and LRC (p < 0.01). In multivariate analysis, leukocytosis remained an independent risk factor associated with poorer OS, PFS and LRC (p < 0.05), independently from tumor stage and length, with higher prognostic value for OS compared with patients' performance status (PS).
Bi-institutional clinical records from consecutive non-operable patients treated between 2003 and 2015 with definitive chemoradiation for locally advanced esophageal carcinoma were reviewed. Leukocytosis and neutrophilia were defined as a leukocyte or neutrophil count over 10 G/L and 7 G/L, respectively. These parameters were studied for their potential correlation with overall survival (OS), progression free survival (PFS), locoregional control (LRC) and distant metastases control (DMC).
Leukocytosis and neutrophilia were independent prognostic factors of poor OS, PFS, and LRC in this bi-institutional series of locally advanced esophageal SCC treated with definitive chemoradiation. Although prospective confirmation is warranted, it is suggested that the leukocyte and neutrophil count parameters might be clinically relevant biomarkers to be considered for further clinical investigations.
探讨白细胞和中性粒细胞计数作为生物标志物在接受单纯放化疗的局部晚期食管鳞状细胞癌(SCC)患者中的预后价值。
共纳入126例患者。分别有33%和35%的患者出现基线白细胞增多和中性粒细胞增多。从放化疗结束起估计的3年总生存率(OS)和无进展生存率(PFS)分别为31%和25%。单因素分析显示,白细胞增多和中性粒细胞增多均与较差的OS、PFS和局部区域控制(LRC)相关(p<0.01)。多因素分析显示,白细胞增多仍然是与较差的OS、PFS和LRC相关的独立危险因素(p<0.05),独立于肿瘤分期和长度,与患者的体能状态(PS)相比,对OS具有更高的预后价值。
回顾了2003年至2015年间连续接受确定性放化疗治疗局部晚期食管癌的非手术患者的双机构临床记录。白细胞增多和中性粒细胞增多分别定义为白细胞计数或中性粒细胞计数超过10 G/L和7 G/L。研究了这些参数与总生存(OS)、无进展生存(PFS)、局部区域控制(LRC)和远处转移控制(DMC)的潜在相关性。
在这个接受确定性放化疗的双机构局部晚期食管SCC系列研究中,白细胞增多和中性粒细胞增多是OS、PFS和LRC较差的独立预后因素。尽管需要前瞻性证实,但建议白细胞和中性粒细胞计数参数可能是临床上相关的生物标志物,有待进一步临床研究。